Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SNN 
Smith & Nephew SNATS Inc (SNN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: SNN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 28.84% | Avg. Invested days 56 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.39B USD | Price to earnings Ratio 30.18 | 1Y Target Price 32.14 |
Price to earnings Ratio 30.18 | 1Y Target Price 32.14 | ||
Volume (30-day avg) 783396 | Beta 0.72 | 52 Weeks Range 23.04 - 30.91 | Updated Date 04/1/2025 |
52 Weeks Range 23.04 - 30.91 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 2.64% | Basic EPS (TTM) 0.94 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.09% | Operating Margin (TTM) 18.71% |
Management Effectiveness
Return on Assets (TTM) 5.45% | Return on Equity (TTM) 7.86% |
Valuation
Trailing PE 30.18 | Forward PE 12.59 | Enterprise Value 14811487059 | Price to Sales(TTM) 2.13 |
Enterprise Value 14811487059 | Price to Sales(TTM) 2.13 | ||
Enterprise Value to Revenue 2.58 | Enterprise Value to EBITDA 12.25 | Shares Outstanding 436755008 | Shares Floating 865975723 |
Shares Outstanding 436755008 | Shares Floating 865975723 | ||
Percent Insiders 0.03 | Percent Institutions 8.13 |
Analyst Ratings
Rating 4 | Target Price 32.55 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Smith & Nephew SNATS Inc
Company Overview
History and Background
Smith & Nephew was founded in Hull, UK in 1856. While Smith & Nephew has a US presence, SNATS Inc. is not an independently traded US stock. This analysis will focus on Smith & Nephew PLC, traded on the NYSE as SNN (ADR). The company evolved from a small pharmacy to a global medical technology company, expanding through organic growth and acquisitions.
Core Business Areas
- Sports Medicine & ENT: Focuses on arthroscopic enabling technologies, soft tissue repair, joint reconstruction, and ear, nose, and throat (ENT) products.
- Orthopaedics: Offers hip and knee implants, trauma and extremities products.
- Advanced Wound Management: Provides products for the treatment and prevention of acute and chronic wounds.
Leadership and Structure
Smith & Nephew's leadership includes a CEO and a board of directors. Organizational structure includes distinct business units for each core business area.
Top Products and Market Share
Key Offerings
- Advanced Wound Management: Offers a range of dressings, negative pressure wound therapy (NPWT) and biologics. Competitors include 3M and Convatec. Market Share is estimated at 14% in 2023.
- Sports Medicine Joint Repair: Offers devices used in arthroscopic surgery. Competitors include Arthrex and Stryker. Market Share is estimated at 23% in 2023.
- Orthopaedic Reconstruction: Provides hip and knee implants. Competitors include Zimmer Biomet, Stryker and Johnson & Johnson. Market Share is estimated at 10% in 2023.
Market Dynamics
Industry Overview
The medical technology industry is characterized by innovation, regulatory oversight, and demographic shifts (aging population).
Positioning
Smith & Nephew is a global player with a strong presence in wound management, sports medicine, and orthopedics. Competitive advantages include a diversified product portfolio and a strong global distribution network.
Total Addressable Market (TAM)
The global medical device market is expected to reach $600 billion. Smith & Nephew is positioned to capture a significant portion, but faces stiff competition.
Upturn SWOT Analysis
Strengths
- Diversified Product Portfolio
- Strong Global Distribution Network
- Established Brand Reputation
- Focus on Innovation
Weaknesses
- Slower Growth Compared to Some Competitors
- Exposure to Pricing Pressures
- Integration Challenges from Acquisitions
Opportunities
- Expanding into Emerging Markets
- Developing Innovative Technologies
- Acquiring Complementary Businesses
- Capitalizing on Aging Population
Threats
- Intense Competition
- Regulatory Changes
- Economic Downturns
- Product Liability Claims
Competitors and Market Share
Key Competitors
- Johnson & Johnson (JNJ)
- Stryker (SYK)
- Zimmer Biomet (ZBH)
Competitive Landscape
Smith & Nephew faces intense competition from larger players. To compete Smith & Nephew must leverage it's wound management expertise.
Major Acquisitions
Osseus Integration Systems
- Year: 2021
- Acquisition Price (USD millions): 200
- Strategic Rationale: Expanded the company's extremities portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been steady, driven by organic growth and acquisitions.
Future Projections: Analysts project moderate revenue growth for Smith & Nephew in the coming years.
Recent Initiatives: Recent initiatives include focusing on high-growth markets and investing in R&D.
Summary
Smith & Nephew is a moderately strong company with a diverse product portfolio. The wound management business is doing well. The company is looking out for intense competition and regulatory changes, especially from Johnson & Johnson (JNJ), Stryker (SYK), and Zimmer Biomet (ZBH).
Similar Companies
- JNJ
- SYK
- ZBH
- BSX
- ABT
Sources and Disclaimers
Data Sources:
- Smith & Nephew PLC Annual Reports
- Industry Analyst Reports
- Company Filings
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions can change rapidly. Note: SNN is an ADR of Smith & Nephew PLC, a UK company.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Smith & Nephew SNATS Inc
Exchange NYSE | Headquaters - | ||
IPO Launch date 1999-11-16 | CEO & Director Dr. Deepak S. Nath Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17349 | Website https://www.smith-nephew.com |
Full time employees 17349 | Website https://www.smith-nephew.com | ||
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.